Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,62 GBX | -0,82% | +39,23% | +44,80% |
25/03 | Caspian Sunrise overweegt verkoop van BNG-contractgebied | AN |
25/03 | AIM WINNERS & VERLOSERS: ImmuPharma verdubbelt order; Aeorema boekt verlies | AN |
Omzet 2021 | 25 mln. 23,18 mln. | Omzet 2022 | 42,95 mln. 39,83 mln. | Marktkapitalisatie | 114 mln. 106 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -5 mln. -4,64 mln. | Nettowinst (verlies) 2022 | 9 mln. 8,35 mln. | EV/omzet 2021 | 5,95 x |
Nettoschuld 2021 | 6 mln. 5,56 mln. | Nettoliquiditeiten 2022 | 3,33 mln. 3,09 mln. | EV/omzet 2022 | 2,58 x |
K/w-verhouding 2021 |
-25,6
x | K/w-verhouding 2022 |
11,6
x | Werknemers | 284 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
2,11% | Vrij verhandelbaar | 12,23% |
1 dag | -0,82% | ||
1 week | +39,23% | ||
Lopende maand | +50,83% | ||
1 maand | +41,96% | ||
3 maanden | +44,80% | ||
6 maanden | +0,56% | ||
Lopend jaar | +44,80% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Kuat Oraziman
CEO | Chief Executive Officer | 61 | 01-11-06 |
Clive Carver
CHM | Chairman | 63 | 01-10-06 |
Nurlybek Ospanov
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Clive Carver
CHM | Chairman | 63 | 01-10-06 |
Kuat Oraziman
CEO | Chief Executive Officer | 61 | 01-11-06 |
SeokWoo Shin
COO | Chief Operating Officer | 57 | 01-01-18 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 3,62 | -0,82% | 997 069 |
27-03-24 | 3,65 | +7,35% | 5 029 134 |
26-03-24 | 3,4 | +13,33% | 4 001 563 |
25-03-24 | 3 | +15,38% | 7 262 797 |
22-03-24 | 2,6 | 0,00% | 577 894 |
uitgestelde koers London S.E., 28 maart 2024 om 11:16 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
+44,80% | 104 mln. | |
+4,82% | 290 mld. | |
+9,28% | 149 mld. | |
+39,38% | 112 mld. | |
+18,00% | 80,93 mld. | |
+4,50% | 73,31 mld. | |
+15,62% | 60,74 mld. | |
+7,52% | 56,91 mld. | |
+4,43% | 46,09 mld. | |
-1,80% | 37,54 mld. |